Rifampin Injection Shortage
Manufacturers report shortage status per product/package to the FDA independently, so the same generic drug can be short from one company while another still has supply -- the table below breaks that down company by company.
| Company | Brand name | Status | Last updated |
|---|---|---|---|
| Mylan Institutional, a Viatris Company | RIFAMPIN | Current | 10/19/2026 |
| Fresenius Kabi USA, LLC | RIFAMPIN | Current | 10/15/2026 |
| Sanofi-Aventis U.S. LLC | — | To Be Discontinued | 04/20/2026 |